Norwegian version of this page

Clinical Retina Research

The main aim of our research is clinical implementation and evaluation of new treatment, and diagnostic modalities for vitreoretinal disorders.

The research group consists of doctors and other health professionals at the Eye Departments of UiO and OUH. We study and treat patients with retinal diseases.

Projects

  • PASS-study. Epiretinal strontium-90 brachytherapy combined with intravitreal injection of bevacizumab (Avastin) for treatment of patients with exudative AMD resistant to anti-VEGF treatment.
  • TESOLA study; Transcorneal Electrical Stimulation for Treatment of patients with Retinitis Pigmentosa – A Multisenter Safety Study with the OkuStim System.
  • INJECT: Investigation of JETREA® in Patients with Confirmed Vitreomacular Traction.
  • Quality registry for treating wet AMD with aflibercept.
  • Initial improvements when converting eyes with treatment-resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks.
  • Uveal melanoma - clinical follow-up and cellular characterization. Clinical follow-up and cellular characterization in bone marrow and primary tumors.
  • DiTAMD – Dimensions of Treatment in Age-related Macular Degeneration. Patient derived tool to measure most important dimensions for patients being treated for neovascular AMD.
  • Patient Reported outcome measures (PROM) in patients treated for  wet AMD.
  • Eylea-2014 study. Plasma concentrations of vascular endothelial growth factor before and after repeated intravitreal aflibercept injections in patients with exudative age-related macular degeneration.
  • Harrier-study. Or Alcon/Novartis. International multicenter study of wet AMD – A new medication (RTH258) versus aflibercept.
  • Primary rhegmatogenous retinal detachment –preoperative status, surgical methods and anatomical outcome.

PhD Projects

  • LUCAS. Lucentis compared to Avastin study. Randomised, double-blind, prospective multicentre study of the effect of intravitreal injection of bevacizumab (Avastin®) compared to ranibizumab (Lucentis®) in patients with exudative Age Related Macular degeneration (AMD) in Norway.
  • Mapping of patients with hereditary retinal disease in Norway.
  • Ultra-Widefield Fundus Autofluorescence in the Diagnosis and Evaluation of Retinal Detachment and Intraocular tumors.

Cooperation

This broad range of methods requires close collaboration with research groups in Norway and abroad.

National

  • Ernst O. Ropstad, Norwegian School of Veternary Science, Oslo
  • Geir Bertelsen, Øyeavdelingen, The Arctic University of Norway, Tromsø

International

  • Kristina Narfström, University of Missoury, Columbia USA
  • Barbara Wilhelm, University of Tübingen, Germany
  • Tunde Peto, Moorfields Eye Hospital NHS Foundation Trust/Institute of Ophthalmology, University College, London, UK
Published Feb. 1, 2016 3:25 PM - Last modified Feb. 1, 2016 3:26 PM

Contact

Group leader

Participants

Detailed list of participants